H Gatica

Tumour necrosis factor (TNF)α −308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis

M Cuchacovich, Lilian Soto, M Edwardes et al. · Scandinavian Journal of Rheumatology · 2006 · 74 citations · Full text

Tumour necrosis factor‐α (TNF‐α) levels and influence of −308 TNF‐α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis

M Cuchacovich, Lorena Ferreira, Marta Aliste et al. · Scandinavian Journal of Rheumatology · 2004 · 73 citations · Full text

Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases.

M Cuchacovich, H Gatica, Salvatore V. Pizzo et al. · PubMed · 2002 · 70 citations

Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with <scp>V</scp>ogt‐<scp>K</scp>oyanagi‐<scp>H</scp>arada disease

Cristhian A. Urzúa, Víctor Velásquez, Pablo Sabat et al. · Acta Ophthalmologica · 2015 · 49 citations · Full text

Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.

M Cuchacovich, Diego Catalán, E Wainstein et al. · PubMed · 2009 · 38 citations